Chengcheng Gong

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2026

Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China.

Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China.

Journal: EClinicalMedicine

Published: July 31, 2025

Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China.

Development and validation of nomograms of outcomes for first-line platinum-based chemotherapy for metastatic triple-negative breast cancer: patient-level analysis of five prospective clinical trials in China.

Journal: Therapeutic advances in medical oncology

Published: July 14, 2025

Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs.

Site-specific ligase-dependent conjugation with ring-opening linker improves safety and stability of HER2-targeting ADCs.

Journal: Nature communications

Published: June 12, 2025

18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival.

18F-fluoroestradiol (18F-FES) PET/CT for guiding first-line treatment in patients with HR + /HER2- metastatic breast cancer: impact on progression free survival.

Journal: European journal of nuclear medicine and molecular imaging

Published: May 07, 2025

Efficacy and safety of utidelone in pretreated patients with metastatic breast cancer in China: a multicenter, real-world study.

Efficacy and safety of utidelone in pretreated patients with metastatic breast cancer in China: a multicenter, real-world study.

Journal: Therapeutic advances in medical oncology

Published: April 20, 2025

Precision diagnosis and treatment of PI3K/AKT/PTEN signaling pathway in HR-positive advanced breast cancer: perspectives from Chinese experts.

Precision diagnosis and treatment of PI3K/AKT/PTEN signaling pathway in HR-positive advanced breast cancer: perspectives from Chinese experts.

Journal: Translational breast cancer research : a journal focusing on translational research in breast cancer

Published: October 14, 2024

Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trials.

Clinicopathological characteristics, evolution, and treatment outcomes of hormone receptor-negative/HER2-low metastatic breast cancer: a pooled analysis of individual patient data from three prospective clinical trials.

Journal: Frontiers in endocrinology

Published: June 14, 2024

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer.

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer.

Journal: Frontiers in endocrinology

Published: July 31, 2023

ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors.

ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors.

Journal: Therapeutic advances in medical oncology

Published: April 21, 2023

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score-matched analysis of real-world data.

Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score-matched analysis of real-world data.

Journal: Therapeutic advances in drug safety

Published: July 28, 2022

Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single- Center Study.

Clinicopathological Analysis and Treatment of Adult Patients with Inflammatory Myofibroblastic Tumor: A 15-Year Single- Center Study.

Journal: Cancer research and treatment

Published: July 26, 2022

Showing 1-12 of 36

Last Updated: 09/26/2026